Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Portfolio Pulse from
Neurocrine Biosciences has announced the commercial availability of CRENESSITY, a first-in-class treatment for Classic Congenital Adrenal Hyperplasia (CAH), in the U.S. The drug is available through PANTHERx Rare pharmacy, with support from Neurocrine Access Support.
December 20, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences has launched CRENESSITY, a new treatment for CAH, in the U.S. This could boost the company's revenue and market presence in the rare disease sector.
The launch of CRENESSITY, a first-in-class treatment for CAH, positions Neurocrine Biosciences as a leader in the rare disease market. The FDA approval and commercial availability in the U.S. are likely to positively impact NBIX's stock price due to potential revenue growth and increased market presence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100